Base Editing
Base editing is a newer form of gene editing designed to make precise single-letter changes in DNA. Instead of making a double-strand break, a base editor uses a modified CRISPR system attached to an enzyme that chemically converts one DNA base into another. It may be useful for diseases caused by certain point mutations, but it has limits: not every mutation is editable, delivery remains difficult, and safety must be studied carefully.
Why it matters
Many rare diseases are caused by small spelling changes in DNA. Base editing could eventually help address some of those changes, but families should understand that precision in concept still requires proof of safety, delivery, durability, and clinical benefit.
Related content
What Is Gene Therapy?
Gene therapy is a treatment approach that tries to address disease at the level of the gene, often by adding, replacing, silencing, or editing genetic instructions.
Dr. Guoping Feng (MIT) on SHANK3 Gene Therapy, Brain Disorders, and What’s Coming Next
Dr. Guoping Feng
Welcome — I’m Ron Kleiman, and this is GENEration Hope. In this episode, I’m joined by Dr. Guoping Feng, Professor of Neuroscience at MIT, affiliated with the McGovern Institute, the Yang Tan Collective, and the Broad Institute. 
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
Source: GENEration Hope editorial analysis